tiprankstipranks
Pure Bioscience (PURE)
OTHER OTC:PURE
US Market

Pure Bioscience (PURE) Price & Analysis

45 Followers

PURE Stock Chart & Stats

$0.05
<$0.01(1.96%)
At close: 4:00 PM EST
$0.05
<$0.01(1.96%)

Bulls Say, Bears Say

Bulls Say
Proprietary SDC TechnologyOwning a distinctive antimicrobial chemistry (SDC) provides an enduring competitive asset: it supports product differentiation, licensing potential, and barriers to entry in sanitation markets. Over months, IP-led product advantages can sustain pricing, partner interest, and recurring product sales.
Diverse Institutional End MarketsServing multiple institutional markets (food processing, healthcare, industrial) creates structural demand and reduces single-market exposure. Institutional sanitation buyers often require validated chemistries and recurring purchases, supporting steadier revenue streams and long-term commercial relationships.
Governance Stability & Financing FlexibilityApproval to increase authorized shares and re-election of directors provides durable corporate flexibility: it preserves avenues for future equity raises, strategic transactions, or compensation programs, and signals continued board continuity to execute financing or partnership strategies.
Bears Say
Negative Shareholder EquityPersistent negative equity and debt that exceeds assets materially weaken capitalization and increase refinancing risk. Over 2–6 months such a capital-structure deficit constrains strategic options, raises cost of capital, and heightens insolvency risk if cash needs spike or lenders tighten.
Consistent Cash BurnRepeated negative operating and free cash flow means the business does not self-fund operations or growth. Sustained cash burn increases reliance on external financing, dilutes shareholders when capital raised, and limits ability to invest in commercialization or scale without securing durable funding sources.
Volatile Revenue & Sustained LossesLarge swings in reported revenue and persistent operating losses undermine predictability and scalability. Volatility complicates budgeting, obscures underlying demand trends, and suggests recent margin improvements may reflect one-offs rather than repeatable performance, challenging long-term planning.

PURE FAQ

What was Pure Bioscience’s price range in the past 12 months?
Pure Bioscience lowest stock price was $0.04 and its highest was $0.21 in the past 12 months.
    What is Pure Bioscience’s market cap?
    Pure Bioscience’s market cap is $9.25M.
      When is Pure Bioscience’s upcoming earnings report date?
      Pure Bioscience’s upcoming earnings report date is Jun 16, 2026 which is in 62 days.
        How were Pure Bioscience’s earnings last quarter?
        Pure Bioscience released its earnings results on Mar 16, 2026. The company reported -$0.007 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.007.
          Is Pure Bioscience overvalued?
          According to Wall Street analysts Pure Bioscience’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Pure Bioscience pay dividends?
            Pure Bioscience does not currently pay dividends.
            What is Pure Bioscience’s EPS estimate?
            Pure Bioscience’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does Pure Bioscience have?
            Pure Bioscience has 111,886,475 shares outstanding.
              What happened to Pure Bioscience’s price movement after its last earnings report?
              Pure Bioscience reported an EPS of -$0.007 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
                Which hedge fund is a major shareholder of Pure Bioscience?
                Currently, no hedge funds are holding shares in PURE
                What is the TipRanks Smart Score and how is it calculated?
                Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                  Company Description

                  Pure Bioscience

                  PURE Bioscience, Inc. develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. The company manufactures and distributes silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent, which offers residual protection, as well as formulates with other compounds. It offers SDC-based disinfecting and sanitizing products, including PURE Hard Surface, a food contact surface sanitizer and disinfectant; PURE Control, a food contact processing aid for fresh produce and raw poultry; PURE Multi-Purpose and Floor Cleaner Concentrate to clean various resilient surfaces, including floors, glass, and food contact surfaces; and PURE Multi-Purpose Hi-Foam Cleaner Concentrate to clean stainless steel equipment, resilient floors, walls, and painted surfaces. The company also provides Axen30, a hard surface disinfectant; Axenohl, an antimicrobial formulation for use as a raw material ingredient in the manufacturing of consumer and commercial disinfecting and sanitizing products; and SILVÉRION, an antimicrobial formulation that is used against bacteria, viruses, yeasts, and molds. PURE Bioscience, Inc. was incorporated in 1992 and is headquartered in Rancho Cucamonga, California.

                  Pure Bioscience (PURE) Earnings & Revenues

                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Mannatech
                  United-Guardian
                  Tantech Holdings
                  Grove Collaborative Holdings
                  Yoshitsu Co. Ltd. Sponsored ADR

                  Ownership Overview

                  0.72%99.28%
                  Insiders
                  0.72% Other Institutional Investors
                  99.28% Public Companies and
                  Individual Investors

                  Options Prices

                  Currently, No data available
                  ---
                  Popular Stocks